ranolazine
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ventricular Premature Complexes
Conditions
Ventricular Premature Complexes, Myocardial Ischemia
Trial Timeline
Dec 1, 2014 → Feb 23, 2018
NCT ID
NCT02360397About ranolazine
ranolazine is a phase 2 stage product being developed by Gilead Sciences for Ventricular Premature Complexes. The current trial status is completed. This product is registered under clinical trial identifier NCT02360397. Target conditions include Ventricular Premature Complexes, Myocardial Ischemia.
What happened to similar drugs?
2 of 11 similar drugs in Ventricular Premature Complexes were approved
Approved (2) Terminated (2) Active (7)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (13)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02360397 | Phase 2 | Completed |
| NCT02251457 | Phase 1 | Completed |
| NCT01721967 | Approved | Completed |
| NCT01705509 | Pre-clinical | Terminated |
| NCT01804543 | Pre-clinical | UNKNOWN |
| NCT01435174 | Approved | Completed |
| NCT02133352 | Approved | Completed |
| NCT01334203 | Approved | Withdrawn |
| NCT01304095 | Approved | UNKNOWN |
| NCT01174173 | Phase 3 | Completed |
| NCT01163734 | Phase 2 | Completed |
| NCT00644332 | Approved | Completed |
| NCT00091429 | Phase 3 | Completed |
Competing Products
20 competing products in Ventricular Premature Complexes